---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-017035"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-26T23:54:08.776226+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enanta Q1 net loss narrows to $22.3M; RSV Phase 2 topline data due Q3 2025

## Summary
- Net loss $22.3M (-$1.05/sh) vs loss $33.4M (-$1.58/sh) YoY; revenue $17M from MAVYRET royalties.
- Cash & securities $216.7M; expects runway into FY2028.
- RSV zelicapavir Phase 2 RSVHR top-line data expected Q3 2025; Dec 2024 pediatric study showed antiviral effect.
- Immunology: EPS-1421 KIT inhibitor IND studies ongoing; STAT6 candidate selection H2 2025; third program announced 2025.
- Filed appeal in patent lawsuit against Pfizer over Paxlovid (Feb 3, 2025).

## SEC filing metadata
- accession: 0000950170-25-017035
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017025017035/0000950170-25-017035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017025017035/enta-20250210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-017035
- JSON: https://secwatch.observer/filing/0000950170-25-017035.json
- Plain text: https://secwatch.observer/filing/0000950170-25-017035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.